Trelis Blanes A, Lago V, Perez Martinez R, Belloch Ripolles V, Montoliu G, Padilla-Iserte P
Cancers (Basel). 2025; 17(5).
PMID: 40075594
PMC: 11899235.
DOI: 10.3390/cancers17050746.
Miguez Medina M, Luzarraga A, Catalan S, Acosta U, Hernandez-Fleury A, Bebia V
Cancers (Basel). 2025; 17(3).
PMID: 39941787
PMC: 11816242.
DOI: 10.3390/cancers17030418.
Schwarz F, Klotz D, Yang R, Brux M, Buchholz F, Harb H
Cancer Gene Ther. 2025; .
PMID: 39915607
DOI: 10.1038/s41417-025-00874-z.
Westbom-Fremer S, Tran L, Ebbesson A, De La Fuente L, Jonsson J, Kannisto P
Cancer Immunol Immunother. 2025; 74(2):56.
PMID: 39751944
PMC: 11699021.
DOI: 10.1007/s00262-024-03911-2.
Fayoud A, Darwish M, Nada E, Helal A, Mohamed N, Elrashedy A
Cureus. 2024; 16(11):e73503.
PMID: 39677200
PMC: 11638381.
DOI: 10.7759/cureus.73503.
Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.
Crabbe M, Opsomer T, Vermeulen K, Ooms M, Segers C
Theranostics. 2024; 14(16):6281-6300.
PMID: 39431018
PMC: 11488094.
DOI: 10.7150/thno.99782.
Para-Aortic Lymphadenectomy in Ovarian, Endometrial, Gastric, and Bladder Cancers: A Systematic Review of Randomized Controlled Trials.
Alouini S, Bakri Y
Cancers (Basel). 2024; 16(19).
PMID: 39410014
PMC: 11475963.
DOI: 10.3390/cancers16193394.
Role of Fyn expression in predicting the sensitivity to platinum‑based chemotherapy in patients with ovarian serous carcinoma.
Uchikura E, Fukuda T, Sengiku T, Noda T, Awazu Y, Wada T
Oncol Lett. 2024; 28(5):525.
PMID: 39268168
PMC: 11391251.
DOI: 10.3892/ol.2024.14658.
MicroRNA-486-3p affects cisplatin resistance in high-grade serous ovarian cancer by regulating TMIGD2: An experimental study.
Wang J, Wu Y
Heliyon. 2024; 10(15):e34978.
PMID: 39145009
PMC: 11320304.
DOI: 10.1016/j.heliyon.2024.e34978.
Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer.
Kulkarni S, Gajjar K, Madhusudan S
Front Oncol. 2024; 14:1414112.
PMID: 39135999
PMC: 11317305.
DOI: 10.3389/fonc.2024.1414112.
External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancer.
Oufkir N, Rouzier R, Paoletti X, Bonneau C
J Ovarian Res. 2024; 17(1):152.
PMID: 39039554
PMC: 11265035.
DOI: 10.1186/s13048-024-01476-3.
ESR Essentials: characterisation and staging of adnexal masses with MRI and CT-practice recommendations by ESUR.
Avesani G, Panico C, Nougaret S, Woitek R, Gui B, Sala E
Eur Radiol. 2024; 34(12):7673-7689.
PMID: 38849662
PMC: 11557651.
DOI: 10.1007/s00330-024-10817-1.
Targeting BRAF pathway in low-grade serous ovarian cancer.
Perrone C, Angioli R, Luvero D, Giannini A, Di Donato V, Cuccu I
J Gynecol Oncol. 2024; 35(4):e104.
PMID: 38768941
PMC: 11262891.
DOI: 10.3802/jgo.2024.35.e104.
Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis.
Zhang X, Zhu B, He M, Dong S
J Ovarian Res. 2024; 17(1):102.
PMID: 38745302
PMC: 11092198.
DOI: 10.1186/s13048-024-01429-w.
FT-Raman and FTIR spectroscopy as a tools showing marker of platinum-resistant phenomena in women suffering from ovarian cancer.
Kluz-Barlowska M, Kluz T, Paja W, Pancerz K, Laczynska-Madera M, Miziak P
Sci Rep. 2024; 14(1):11025.
PMID: 38744861
PMC: 11094164.
DOI: 10.1038/s41598-024-61775-z.
Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer.
Nozaki T, Sakamoto I, Kagami K, Amemiya K, Hirotsu Y, Mochizuki H
J Gynecol Oncol. 2024; 35(4):e55.
PMID: 38330378
PMC: 11262903.
DOI: 10.3802/jgo.2024.35.e55.
Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer-Quality of Life Evaluation Research) Prospective, International, Multicentre Study.
Lakhiani A, Cummins C, Kumar S, Long J, Arora V, Balega J
Cancers (Basel). 2024; 16(1).
PMID: 38201503
PMC: 10778036.
DOI: 10.3390/cancers16010075.
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ho G, Vandenberg C, Lim R, Christie E, Garsed D, Lieschke E
Ther Adv Med Oncol. 2023; 15:17588359231208674.
PMID: 38028140
PMC: 10666702.
DOI: 10.1177/17588359231208674.
FT-Raman data analyzed by multivariate and machine learning as a new methods for detection spectroscopy marker of platinum-resistant women suffering from ovarian cancer.
Kluz-Barlowska M, Kluz T, Paja W, Sarzynski J, Laczynska-Madera M, Odrzywolski A
Sci Rep. 2023; 13(1):20772.
PMID: 38008780
PMC: 10679116.
DOI: 10.1038/s41598-023-48169-3.
Rationale and Methodologic Approach for Assessing Ovarian Cancer Treatment and Gynecologic Oncologist Involvement in the Midwest Region of the United States.
Ng D, Ross W, Traverso-Ortiz M, Rim S, Wike J, Moore A
J Registry Manag. 2023; 50(3):85-91.
PMID: 37941740
PMC: 10629802.
